Clinical trials: Clear Cell Renal Cancer
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug[s]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab.
- Trial name
- NCT03972657
- Testing
- REGN5678, Cemiplimab
- Where
- 27 sites in United States, South Korea
- Volunteers
- 345 people
- Sponsor
- Regeneron Pharmaceuticals
Kidney Cancer
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
Background: Gene transfer is a new cancer therapy takes white blood cells from a person and grows them in a lab. The cells are changed with a virus to attack tumor cells, then returned to the person.
- Trial name
- NCT03354390
- Testing
- cell infusion
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Metastatic Renal Cell Carcinoma
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
SUNNIFORECAST (Standard of Care vs. Nivolumab + Ipilimumab as First line treatment of renal cell cancer of non-clear cell subtypes) is a Phase II, randomized, open-label investigator initiated trial (IIT) of Nivolumab…
- Trial name
- NCT03075423
- Testing
- Ipilimumab plus nivolumab, Standard Therapy
- Where
- 30 sites in Belgium, Czechia and 5 more
- Volunteers
- 316 people
- Sponsor
- Goethe University
Advanced Cancer, Clear Cell Renal Cell Carcinoma
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT05663710
- Testing
- 177Lu girentuximab, Nivolumab, Cabozantinib
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Clear-cell Renal Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Disease and Stage: Metastatic and locally advanced clear cell renal carcinoma An open-label, exploratory, single-arm, multicenter trial.
- Trial name
- NEORAD (NCT01715935)
- Testing
- Everolimus
- Where
- 10 sites in France
- Volunteers
- 25 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Clear-Cell Renal Carcinoma
Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
Background: -Clear-cell renal cell carcinoma (ccRCC) is a kind of kidney cancer. The drug avelumab may help direct the immune response to the tumors and can prolong the immune response.
- Trial name
- NCT04150562
- Testing
- rhIL-15, Avelumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
The purpose of this study is to determine whether BNC105P in combination with/following everolimus is effective in the treatment of progressive metastatic clear cell renal cell carcinoma following prior tyrosine kinase inhibitors.
- Trial name
- NCT01034631
- Testing
- Everolimus, BNC105P
- Where
- 108 sites in United States, Australia and 1 more
- Volunteers
- 154 people
- Sponsor
- Hoosier Cancer Research Network
Bellini Carcinoma, Collecting Duct Carcinoma
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
This is a single-arm, monocentric, phase II trial, enrolling patients with histological diagnosis of collecting duct carcinoma and renal medullary carcinoma with locally advanced or metastatic disease who will be treated with…
- Conditions
- Bellini Carcinoma, Collecting Duct Carcinoma, Renal Medullary Carcinoma
- Trial name
- REPRINT (NCT06302569)
- Testing
- Pembrolizumab + Enfortumab Vedotin
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Giuseppe Procopio
Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors.
- Conditions
- Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma
- Trial name
- NCT00335556
- Testing
- Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Conventional Surgery
- Where
- 187 sites in United States, Australia and 3 more
- Volunteers
- 291 people
- Sponsor
- Children's Oncology Group
Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
This phase I trial studies the side effects and best dose of aldesleukin when given together with pembrolizumab in treating patients with kidney cancer that has spread to other parts of the body.
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- NCT03260504
- Testing
- Aldesleukin, Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
This randomized phase III trial studies how well pazopanib hydrochloride works compared to placebo in treating patients with kidney cancer that has spread to other parts of the body and have no evidence of disease after surgery.
- Trial name
- NCT01575548
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Pazopanib Hydrochloride
- Where
- 579 sites in United States
- Volunteers
- 129 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
This trial aims to prospectively assess the safety and efficiency of Fluzoparib in metastatic non-clear cell renal cell carcinoma
- Trial name
- NCT04535687
- Testing
- Fluzoparib
- Where
- China
- Volunteers
- 1 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Clear Cell Renal Cell Carcinoma (ccRCC)
Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM
68Ga-NYM096 is a carbonic anhydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for the detection of clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT07768306
- Testing
- 68Ga-NYM096 injection
- Volunteers
- 20 people
- Sponsor
- Norroy Bioscience Co., LTD
Clear Cell Renal Cell Carcinoma (ccRCC)
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer
Phase I and multicenter study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with clear cell renal cell carcinoma.
- Trial name
- OncoCAIX (NCT06840548)
- Testing
- [68Ga]Ga-OncoCAIX
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Philogen S.p.A.
Clear Cell Renal Cell Carcinoma (ccRCC)
Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients
This study aims to investigate the role of HPGD in clear cell renal cell carcinoma (ccRCC). Specifically, it will focus on HPGD's impact on proliferation, epithelial-mesenchymal transition (EMT), and prognosis.
- Trial name
- HPGD-ccRCC (NCT06778538)
- Testing
- Immunohistochemistry; WB; PCR
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shang Panfeng
Retinoblastoma, Clear Cell Sarcoma
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
This is a Phase I trial with new experimental drugs such as simvastatin in combination with topotecan and cyclophosphamide in the hopes of finding a drug that may work against tumors that have come back or that have not responded…
- Conditions
- Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Rhabdoid Tumor
- Trial name
- AflacST1402 (NCT02390843)
- Testing
- Simvastatin, Cyclophosphamide, Topotecan
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Emory University
Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Patients with advanced renal cell carcinoma (RCC) are classified according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria in three risk-groups: favourable, intermediate and poor.
- Conditions
- Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
- Trial name
- FLIPPER (NCT01521715)
- Testing
- Pazopanib
- Where
- 8 sites in Germany
- Volunteers
- 44 people
- Sponsor
- iOMEDICO AG
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Kidney Cancer
Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
RATIONALE: When irradiated donor lymphocytes are infused into the patient they may help the patient's immune system kill tumor cells.
- Trial name
- NCT00176501
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rutgers, The State University of New Jersey
RCC, Renal Cell Cancer
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
The primary objective is to evaluate the improvement in Objective Response Rate (ORR) achieved with Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) in combination with Lenvatinib or…
- Trial name
- NCT07277972
- Testing
- Iparomlimab and Tuvonralimab Injection in combination with Lenvatinib or Axitinib
- Volunteers
- 36 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital